Phibro Animal Health (NASDAQ:PAHC) Shares Gap Down – Time to Sell?

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) gapped down before the market opened on Monday . The stock had previously closed at $41.61, but opened at $39.00. Phibro Animal Health shares last traded at $39.3150, with a volume of 3,639 shares trading hands.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PAHC. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. JPMorgan Chase & Co. raised their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Phibro Animal Health presently has a consensus rating of “Hold” and an average price target of $31.40.

Phibro Animal Health Stock Up 1.6%

The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32. The business’s 50-day moving average is $40.16 and its two-hundred day moving average is $37.57. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of 23.86, a price-to-earnings-growth ratio of 1.10 and a beta of 0.79.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The firm had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were paid a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. Phibro Animal Health’s dividend payout ratio is 28.92%.

Insider Transactions at Phibro Animal Health

In other news, CEO Jack Bendheim sold 38,303 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $45.29, for a total value of $1,734,742.87. Following the sale, the chief executive officer directly owned 20,577 shares in the company, valued at $931,932.33. This represents a 65.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 156,920 shares of company stock worth $6,798,319 over the last ninety days. Insiders own 50.13% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

A number of large investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in Phibro Animal Health by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 554,927 shares of the company’s stock worth $14,175,000 after acquiring an additional 7,841 shares in the last quarter. Millennium Management LLC lifted its holdings in Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after buying an additional 154,281 shares in the last quarter. Ranger Investment Management L.P. boosted its position in Phibro Animal Health by 101.1% in the 2nd quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock valued at $9,143,000 after buying an additional 179,975 shares during the last quarter. Invesco Ltd. grew its stake in shares of Phibro Animal Health by 22.5% during the third quarter. Invesco Ltd. now owns 322,299 shares of the company’s stock valued at $13,040,000 after acquiring an additional 59,226 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Phibro Animal Health by 9.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 301,605 shares of the company’s stock worth $12,203,000 after acquiring an additional 26,539 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.